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ABSTRACT A series of diastereoisomers of endomorphin-1 (EM1, Tyr1-Pro2-Trp3-Phe4-NH2) have been synthesized and
their potency measured using the guinea pig ileum assay. [D-Phe4]EM1 possessed 1/10 the potency of EM1, while potencies
of [D-Tyr1]EM1 and [D-Trp3]EM1 were 50- and 100-fold lower, respectively. Drastic loss of activity occurred in the [D-Pro2]EM1
peptide. The structural determinants for the inactivity and reduced potency of the diastereoisomers were investigated using
NMR spectroscopy and conformational analysis. Simulations of trans-[D-Pro2]EM1 using NOE-derived distance constraints
afforded well-defined structures in which Tyr and Trp side chains stack against the proline ring. The inactivity of [D-Pro2]EM1
was explained by structural comparison with EM1 (Podlogar et al.,1998, FEBS Lett. 439:13–20). The two peptides showed an
opposite orientation of the Trp3 residue with respect to Tyr1, thus suggesting a role of Pro2 as a stereochemical spacer in
orienting Trp3 and Phe4 toward regions suitable for -receptor interaction. The agonist activity of [D-Tyr1]EM1 and
[D-Trp3]EM1 was attributed to their ability to adopt low-energy conformations that mimic those of EM1. The requirements for
-receptor activation were examined further by comparing EM1 with the -peptide [D-Ala2, MePhe4, Gly-ol]-enkephalin
(DAMGO). Conformations of DAMGO with a Tyr1-MePhe4 phenyl ring separation of 12 Å were found to mimic Tyr1-Phe4 of
EM1, thus suggesting overlapping binding modes between these two peptides.
INTRODUCTION
Morphine and endogenous opioid peptides share a common
opioid core in which the spatial disposition of a cationic
amine, a phenolic ring, and an additional hydrophobic group
are necessary to elicit function at opioid receptors (Casy,
1993). However, the conformational flexibility of opioid
peptides has hampered numerous attempts at determining
the relationship between the solution conformation and ac-
tivity using spectroscopic and modeling methods. Insights
into the conformational requirements of peptide binding
have been obtained through the synthesis of analogs with a
more rigid backbone scaffold (Mosberg et al., 1983; Schiller
et al., 1992), or by studies in media that promote structure,
such as viscous solvents (Picone et al., 1990; Amodeo et al.,
1998), lipids (Milon et al., 1990), or lyotropic liquid crystals
(Kimura et al., 1997).
Two novel opioid peptides have recently been isolated
from mammalian brains (Zadina et al., 1997). These tet-
rapeptides, Tyr-Pro-Trp-Phe-NH2 and Tyr-Pro-Phe-Phe-
NH2, have been called endomorphins (denoted EM1 and
EM2, respectively, in Fig. 1) because they are the first
reported brain peptides with high affinity and selectivity for
the -opioid receptor (Zadina et al., 1997). The endomor-
phin structures are particularly amenable to conformational
studies, as they contain a conformationally restricted proline
at the second position. As such, the endomorphins are in the
same class of peptides as morphiceptin (Chang et al., 1981),
PL017 (Chang et al., 1983), and Tyr-W-MIF-1 (Zadina et
al., 1997), shown in Fig. 1, in which a Pro at the second
position confers high selectivity on the -opioid receptor.
The affinity of these peptides greatly depends on the nature
of the amino acid at the fourth position. For example, the
affinity increases fivefold upon substitution of Gly in Tyr-
W-MIF-1 with a hydrophobic residue and more than 50
times if Phe replaces Gly, as in EM1 (Zadina et al., 1997).
Similarly, Tyr-W-MIF-1 showed minimal activation of G-
proteins, while the efficacy of EM1 is 65–78% that of the
potent -opioid peptide [D-Ala2, MePhe4, Gly-ol]-enkepha-
lin (DAMGO, Fig. 1) (Alt et al., 1998; Harrison et al., 1998;
Narita et al., 1998; Sim et al., 1998).
The solution structure of EM1 has been reported using
NMR spectroscopy and conformational analysis (Podlogar
et al., 1998). The existence of a -selectivity pocket was
proposed based on structural similarity with the -peptide
PL017 structure. However, the structure of a single com-
pound does not allow exploration of the full range of ac-
cessible pharmacophoric conformations. In this work, we
have systematically inverted the stereochemistry at each of
the four positions of EM1 to explore how changes in con-
formation affect the biological potency of EM1. By com-
paring diastereoisomers of different potency and activity at
the -opioid receptor, it was possible to reduce the range of
accessible conformers to a smaller number of “bioactive”
candidates. The results have revealed the probable role of
proline as a stereochemical spacer in receptor recognition
and have allowed isolation of the role of each of the three
aromatic residues in the activation of -opioid receptors by
EM1. The putative bioactive conformation of EM1 was
compared with that of DAMGO to evaluate any similarities
or differences in the conformations of these two peptides.
MATERIALS AND METHODS
Synthesis of endomorphin-1 analogs
EM1, [D-Tyr1]EM1, [D-Pro2]EM1, [D-Trp3]EM1, and [D-Phe4]EM1 were
obtained from the Microchemical Facility of the University of Minnesota.
The peptides were synthesized by a stepwise solid-phase procedure using
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standard fluoren-9-ylmethoxy carbonyl (Fmoc) chemistry. The structure of
the peptides was confirmed by amino acid analysis and fast-bombardment
mass spectroscopy (FAB-MS). Purification was obtained using a high-
performance liquid chromatography system with a reverse-phase C18 col-
umn. The purity was 88% for [D-Tyr1]EM1 and 93% or greater for the
remaining peptides.
Pharmacology: guinea pig ileal
longitudinal method
The guinea pig ileal (GPI) preparation was prepared by the method of Rang
(1964), and agonist activity was measured as described previously (Por-
toghese and Takemori, 1985; Schwartz et al., 1997). GPI preparations
contain functional - and -opioid receptors. Evaluation of a possible
antagonist component of [D-Pro2]EM1 was accomplished by incubating the
peptide (1 M) for 15 min with the preparation before the testing with the
-agonist morphine or the -agonist ethylketazocine. Pretreatment with
antagonists nor-binaltorphimine (nor-BNI) (20 nM) (Portoghese et al.,
1987) or naltrexone (100 nM) was employed to demonstrate interaction at
- or -opioid receptors, respectively.
NMR spectroscopy
Five-millimeter tubes (Kontes, Vineland, NJ) and dimethyl sulfoxide-d6
(DMSO-d6) (99.9% isotopic purity; Cambridge Isotope Laboratories, An-
dover, MA) were used for NMR spectra acquisition. The peptide concen-
tration was 8 mM in DMSO-d6. A Varian INOVA 800-MHz and a
Unity-INOVA 600 MHz Varian spectrometer with VNMR 6.1 software
were used for one-dimensional (1-D) and two-dimensional (2-D) spectra,
respectively. Proton 1-D spectra were acquired using 128 increments with
16K data size. A set of 1-D experiments with temperatures between 25°C
and 45°C were performed to measure temperature coefficients of the amide
protons. Two-dimensional spectra were acquired using standard pulse
programs available in the Varian software library. TOCSY spectra were
recorded at 25o and 45°C with mixing times of 50 and 60 ms, respectively,
while mixing times of 400 ms and 300 ms were used for NOESY and
DQF-COSY experiments at 25°C, respectively. 1H-13C HMQC data were
collected with a proton spectral width of 5000 Hz and an acquisition time
of 0.21 and 16 scans/increment; the carbon spectral width was 20,000 Hz
with 512 increments in the 13C dimension. Chemical shifts for 13C were
referenced from the DMSO peak position. NOESY experiments were also
performed for a sample at 10 mM in 90% H2O/10% D2O at pH 4.1. Data
were collected at 25°C with a mixing time of 400 ms. Water suppression
was accomplished using the Watergate suppression sequence.
Data were processed using the NMRPipe suite of programs (Delagio et
al., 1995). NOE intensities were classified into three groups according to a
calibration against the peak intensity of nondegenerous geminal protons.
The three groups (strong, medium, and weak) were placed in categories
TABLE 1 The effect of endomorphin-1 and its analogs on
the guinea pig ileum preparation
Peptide IC50 (nM) (n)* Agonist potency Ratio†
EM1 6.7  2.0 (3) 10.9  2.9
[D]-Tyr1]EM1 303  101 (3) 0.24  0.09
[D-Pro2]EM1 28% (6)‡ —
[D-Trp3]EM1 553  135 (4) 0.14  0.05
[D-Phe4]EM1 127  13 (3) 0.99  0.64
*Values in parentheses are the number of determinations.
†The IC50 of the agonist divided by the IC50 of morphine in the same
preparation.
‡Maximum response at 1 M peptide.
FIGURE 1 Schematic diagram of
-selective opioid peptides discussed
in the current study.
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with upper distance limits of 2.5, 3.6, or 5.0 Å, respectively; all lower
bounds were set at 1.8 Å (Williamson et al., 1985).
Conformational analysis
Systematic conformational searches were obtained using the SPASMS
module of AMBER5.0 and the force field of Cornell et al. (1995) as
recently updated for the peptide backbone parameters (parm96.dat) (Case
et al., 1997). Energy minimization was carried out without a nonbonded
cutoff to a convergence of 0.0005 in the gradient and a distance-dependent
dielectric constant of 4r. The peptide was considered uncharged to mini-
mize N- and C-termina artifacts. A simulated annealing protocol was used
to obtain NMR-derived structures. A set of 200 randomly generated con-
formations was subjected to a 15-ps protocol during which the temperature
of the system was increased to 1200 K and then rapidly cooled. The
restraining potential was a flat square-bottom potential with parabolic sides
and a force constant of 32 kcal/mol. The structures were then energy
minimized and clustered using PADRE (Stahl and Walter, 1995), with a
0.85 Å cutoff for the rms deviation between structures.
Molecular dynamics simulations
Molecular dynamics simulations in aqueous solutions were obtained using
AMBER5 (Case et al., 1997), by placing the peptides in a box with
dimensions of 36  34  32 Å, containing a total of 1195 equilibrated
water molecules. After 500 steps of energy minimization, the system was
equilibrated by raising the temperature from 0 to 100 K for 5 ps, from 100
to 300 K for 15 ps, and continuing at 300K up to 100 ps under constant
volume conditions. NOE-derived distance constraints were imposed during
the first 10 ps of simulation and then slowly released up to 50 ps, after
which they were set to zero. Simulations were then continued at constant
pressure at 300 K with no constraints up to the indicated time.
FIGURE 2 1-D 800-MHz NMR spectrum of [D-Pro2]EM1 in DMSO-d6 (8 mM, 25°C). Inset shows details of the amide, Tyr-OH, and Trp-NH1 chemical
shift region. The subscripts t and c refer to the trans and cis rotameters, respectively.
TABLE 2 Observed NOE cross-peaks of [D-Pro2]EM1 in
DMSO-d6
NOE observed NOE* intensity NOE observed NOE* intensity
W1-WNH m WNH-FNH s
W1-W w FNH-F m
W1-P m FNH-F s
W1-P m FNH-F3,5 w
W1-P w FNH-P m
W4-P w FNH-P w
W4-P w FNH-P w
W2-FNH m FNH-W s
W2-P s FNH-W m
W2-P m FNH-W s
WNH-W m FNH-W4 w
WNH-W s Y2,6-P m
WNH-W2 m Y2,6-P m
WNH-W4 w Y2,6-P w
WNH-P s Y2,6-P w
WNH-P s Y3,5-P m
WNH-P s Y3,5-P w
WNH-P m Y3,5-P w
*NOE intensities are classified as weak, w  5.0 Å; medium, m  3.6 Å;
or strong, s  2.9 Å.
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RESULTS
Endomorphin-1 and its diastereoisomers were evaluated for
their biological activity, using the electrically stimulated
GPI preparation (Portoghese and Takemori, 1985) (Table
1). Endomorphin-1 was 10-fold more potent than morphine
and twofold more potent than DAMGO (results not shown),
in agreement with a previous report (Zadina et al., 1997).
Significantly, inversion of the Tyr1 chiral center afforded a
50-fold reduction in potency relative to EM1. Inversion of
Phe4 resulted in a 10-fold loss of potency, while that of
[D-Trp3]EM1 was 100-fold lower. Activity was lost upon
inversion of chirality at Pro2 in the [D-Pro2]EM1. This was
due to the inability of this peptide to fully activate opioid
receptors at a concentration (1 M) that was 100-fold
greater than the IC50 value of EM1. Furthermore,
[D-Pro2]EM1 was not an antagonist at either the - or
-receptor, as it was unable to shift the dose-response curve
of either morphine or ethylketazocine. While EM1 has a
20,000-fold selectivity over the -receptor (Zadina et al.,
1997), it was unlikely that the diastereoisomers could show
agonist activity at the -receptor. This was indeed the case,
given that incubation of the GPI with the -selective antag-
onist norBNI did not shift the dose-response curves of the
diastereoisomers. The interaction with opioid receptors was
demonstrated by the nanomolar potency of naltrexone in
antagonizing the agonism of the peptides.
The 1-D NMR spectrum of [D-Pro2]EM1 in DMSO-d6
(Fig. 2) exhibited two populations of conformers corre-
sponding to the cis and trans isomers. Interestingly, the
relative chemical shifts between the major and minor con-
formers of the Tyr-OH and Trp-NH1 protons were in an
opposite relation compared to those observed in EM1 in
DMSO-d6 (Podlogar et al., 1998). The assignment of the
spectral features to either cis or trans isomer was therefore
confirmed using HMQC spectra. The difference between
the 13C chemical shifts of  (27.94 ppm) and  (23.02 ppm)
carbons of [D-Pro2] EM1 was less than 5 ppm, which is
typical of the trans conformation of proline (Dorman and
Bovey, 1973; D’Ursi et al., 1992). The major isomer was
therefore assigned to the trans conformation. Integration of
the two peaks at 10.75 and 10.80 ppm gave 11% cis and
89% trans populations. Spectral features corresponding to
the cis isomer presented additional complexity, as three
separate forms of this isomer could be distinguished in both
the 1-D and TOCSY data for DMSO-d6.
The amide proton temperature coefficients, NH, of both
trans- and cis-EM1were found to be in excess of 3.0  103
ppm/ K, indicating an absence of intramolecular hydrogen
bonds in DMSO-d6. The smaller NH value of Trp (NH
 3.5 103 ppm/ K) compared to Phe (NH(Phe) 5.5
103 ppm/ K) in the trans isomer suggests that this amide is
less accessible to solvent. Changes in spectral bandwidth or
C proton chemical shifts were not observed between 0.5
and 8 mM in DMSO-d6, suggesting that aggregation does
not occur at the concentration used here. This result is in
agreement with the lower tendency of cationic opioid pep-
tides to aggregate compared to dipolar peptides (Higashijma
et al., 1978; Carpenter et al., 1996).
A total of 36 NOE cross-peaks were observed for the
trans isomer in DMSO-d6 (summarized in Table 2). Rele-
vant regions of the NOE spectrum are shown Fig. 3. All but
one of the NOE cross-peaks from backbone protons corre-
sponded to sequential (i, i 	 1) interactions with an addi-
FIGURE 3 Part of the 600-MHz NOESY
spectrum of [D-Pro2]EM1 in DMSO-d6 (8
mM, 25°C), showing correlation of proline
ring protons with Trp and Tyr aromatic ring
protons.
FIGURE 4 Low-energy conformations of [D-Pro2] EM1consistent with
NOE data. Structures are overlapped by rms fit of the backbone atoms of
Pro, Trp, and Phe.
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tional (i, i 	 2) NOE signal between Pro-CH and Phe-NH.
NOE cross-peaks were observed between the side chains of
Pro and Trp and Pro and Tyr (Fig. 3), suggesting stacking of
the two aromatic rings against proline. NOE data arising
from the cis isomer of the peptide could not be fully as-
signed because of a low signal-to-noise ratio in addition to the
spectral complexity of the cis isomer. Structural NOE cross-
peaks were not observed for [D-Pro2]EM1 in aqueous solution.
The NOE cross-peaks for the trans isomer were classified
as weak (w), medium (m), and strong (s) and used as
distance constraints in the simulated annealing protocol.
Distances were assigned as s  2.9 Å, m  3.6 Å, and w 
5.0 Å, with a closest distance limit of 1.8 Å (Williamson et
al., 1985). Of the 200 conformations generated in this fash-
ion, five unique structures remained after clustering (shown
in Fig. 4). No significant violations of NOE distance con-
straints were observed. A comparison among the five struc-
tures yielded a rms deviation of 0.84  0.35 Å for the
backbone atoms and an all-atom rms of 1.53  0.43 Å. The
deviations were largely due to Phe4, which is less structur-
ally defined because NOE cross-peaks between its aromatic
ring and the other residues were not observed. Tyrosine and
Trp side chains, however, were well characterized, with
rotamers 	1(Tyr)  t and 	1(Trp)  g
.
The proline residue functions as a spacer between the
tyramine moiety of Tyr and the aromatic residues at posi-
tions 3 and 4. Stereochemical inversion at Pro could affect
either the conformation of the preceding (Tyr1) or following
TABLE 3 Minimum-energy conformations of Tyr-D-Pro-NMe, Tyr-Pro-NMe, and D-Tyr-Pro-NMe*
Peptide No. E† v‡
Tyr Pro

  	1  

Tyr-D-Pro-NMe 1D 0.00 0.65 136.3 177.8 
177.8 54.0 45.5
2D 0.92 0.14 104.9 2.9 
173.5 67.3 49.4
3D 1.31 0.07 127.4 3.1 
63.1 59.6 46.7
4D 1.51 0.05 147.3 179.9 67.3 52.0 45.7
5D 1.77 0.03 
68.0 
178.1 172.2 52.7 46.5
6D 1.79 0.03 144.7 
178.8 
63.4 52.1 45.8
7D 1.91 0.03 134.2 3.6 69.5 61.7 50.1
8D 4.79 0.00 
74.3 8.8 173.6 58.0 48.6
9D 4.84 0.00 
45.7 
177.6 71.5 53.5 49.9
10D 4.91 0.00 
64.7 
177.1 
65.0 54.6 44.9
Tyr-Pro-NMe 1L 0.00 0.69 127.3 
177.2 178.5 
71.7 
51.1
2L 0.67 0.22 137.8 
2.6 
176.3 
72.8 
38.2
3L 1.53 0.05 149.8 
178.0 70.8 
69.9 
51.7
4L 2.42 0.01 151.4 
3.1 68.0 
72.4 
38.6
5L 2.45 0.01 150.1 
0.3 
65.2 
72.6 
39.8
6L 2.66 0.01 149.0 179.1 
63.3 
69.8 
40.4
7L 4.72 0.00 
59.4 
178.3 178.3 
69.8 
38.1
D-Tyr-Pro-NMe 1 0.00 0.63 
136.2 
178.6 177.6 
56.0 147.9
2 0.7 0.21 
110.5 
2.4 173.9 
65.6 143.4
3 1.4 0.06 
147.6 179.5 
67.3 
54.1 136.7
4 1.8 0.03 
144.8 178.4 63.0 
54.2 136.9
5 1.9 0.03 
121.9 
0.2 70.4 
60.4 153.7
6 2.1 0.02 
134.3 
2.9 
69.3 
62.3 136.5
7 2.8 0.01 66.9 175.2 
173.0 
55.5 133.0
8 4.8 0.00 65.1 176.7 65.1 
56.2 139.1
9 4.9 0.00 74.0 
7.5 
173.8 
58.9 144.0
10 4.9 0.00 46.6 175.0 
69.0 
52.6 133.9
*Angles are defined in the schematic above. All angles are in degrees.
†E  E 
 E°, where E°  17.35 kcal/mol for Tyr-D-Pro-NMe, E°  15.96 kcal/mol for Tyr-Pro-NMe, and E°  16.1 kcal/mol for D-Tyr-Pro-NMe.
‡Statistical weights, expressed as a normalized Boltzmann factor vi  exp(
Ei/RT)/i(
Ei/RT), where T  300 K and R is the gas constant.
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(Trp3) residue, effectively changing the relative orientation
of these two residues. The effect of chirality on the confor-
mation of the Tyr-Pro fragment was examined using sys-
tematic conformational searches on the fragments Tyr-Pro-
NMe, Tyr-D-Pro-NMe, and D-Tyr-Pro-NMe by varying the

(Tyr), (Tyr), and 	1(Tyr) dihedral angles. Proline was
placed in the  (
70°, 

50°) or  (
70°, 

120°) conformation, yielding similar results in the two cases.
The calculated cis/trans population ratios of 26/74% for
Tyr-Pro-NMe and 23/77% for Tyr-D-Pro-NMe (Table 3) are
in good agreement with the NMR data of EM1 (Podlogar et
al., 1998) and its [D-Pro2] diastereoisomer. The lowest en-
ergy conformer is similar in the two L-Tyr peptides and
corresponds to a conformation with 
(Tyr) in an extended
or  conformation, trans-(Tyr), and trans-	1(Tyr) (con-
formations 1D and 1L in Table 3). Conformations with

(Tyr)  140o are preferred over those with 
(Tyr) 

65o, in agreement with previous computational studies of
Pro-containing peptides (Ne´methy et al., 1992). D-substitu-
tion of Tyr resulted in a reversal of the 
(Tyr) dihedral
angle, with conformations with 
(Tyr)  
135° preferred
over those with 
(Tyr)  65° (Table 3).
The conformational properties of [D-Pro2]EM1 and
[D-Tyr1]EM1 were further examined using molecular dy-
namics simulations with explicit aqueous solvent. The dis-
tribution of backbone dihedral angles during a 4-ns simu-
lation of [D-Pro2]EM1 showed correlated motion in the
Pro-Trp region, where two major conformations are sam-
pled (conformations A and B in Fig. 5 a), while conforma-
tional sampling of Phe was independent of the other resi-
dues. Of the two conformations observed, A, with 
(Pro) 

150° and (Trp)  
140°, resulted in interactions be-
tween the Tyr, Pro, and Trp side chains and closely resem-
bled the NMR-derived structure, with rms deviations of
1–1.5 Å. The side-chain dihedral angles showed confor-
mational preferences for 	1(Tyr)  t, 	1(Trp)  g
, and
	1(Phe)  g
. Intramolecular hydrogen bonds were not
observed throughout the simulation. Molecular dynamics
simulations of the [D-Tyr1]EM1 peptide (Fig. 5 b) showed
trajectories of the Pro-Trp-Phe residues similar to those
observed for EM1 (Podlogar et al., 1998). However, stere-
ochemical inversion resulted in a reversal of the 
(Tyr)
dihedral angle, and, in this case, both the 
(Tyr)  65° and

(Tyr)  
135° conformations were populated.
FIGURE 5 (a) Distribution of dihedral angles during a
4-ns simulation of solvated [D-Pro2]EM1. Labels A and B
denote the two major conformations observed during the
trajectory. (b) Distribution of dihedral angles during a 6-ns
simulation of solvated [D-Tyr1]EM1. Angles shown: 
(thin line), 
 (heavy line), 	1 (dashed line).
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The conformational dynamics of EM1 and its [D-Pro2]
and [D-Tyr1] diastereoisomers were compared with those of
DAMGO. This peptide exists in cis-trans equilibrium with
respect to the Gly3-MePhe4 amide bond, but the most pop-
ulated trans conformation was proposed to represent the
bioactive form of the peptide based on NMR data and
conformational analysis (Penkler et al., 1993). The trans
isomer was therefore chosen for molecular dynamics sim-
ulations in explicit solvent. Calculations were performed on
the N-terminal tetrapeptide-methylamide fragment, Tyr-D-
Ala-Gly-MePhe-N-CH3 (tTAGP), to facilitate comparison
with a previous conformational analysis (Penkler et al.,
1993). Results are shown in Fig. 6. The first two residues
sampled a wider range of conformations compared to the
Tyr-Pro fragment (Figs. 5 and 6), as the angles 
(Tyr) 

60° and (D-Ala)  140° were also populated. The sharp
distributions at 
(MePhe)  50° and 	1(MePhe)  
60°
reflected the steric restriction imparted by the N-methyl
group of MePhe. The “hinge” region, comprising 
(D-Ala)
and (Gly), however, is flexible and has the effect of
changing the relative orientation and distance, D, of the two
aromatic groups. The great majority of structures had D
values between 8 and 14 Å, but structures with D 6 Å and
D  17 Å occurred as well. Overall, MD simulations
resulted in a more exhaustive conformational sampling
compared to previous approaches using conformational
searches (Penkler et al., 1993).
DISCUSSION
The NMR data of trans-[D-Pro2]EM1 in DMSO-d6 outline a
well-defined conformation with stacking of the Tyr, Pro,
and Trp rings. These results are in sharp contrast with
previous NMR data of trans-EM1 in DMSO-d6, where only
few NOE could be discerned, while cis-EM1 adopted a
more compact conformation (Podlogar et al., 1998). The
relevance of the NMR-derived structures to the loss of
biological activity upon inversion of chirality at Pro is better
understood by comparing the trans-EM1 (Podlogar et al.,
1998) and trans-[D-Pro2]EM1 structures. Trans-EM1 and
trans-[D-Pro2]EM1 were overlapped using the same confor-
mation of the tyramine moiety, with 
(Tyr)  140° and
	1(Tyr)  t, as shown in Fig. 7. Results on Tyr-Pro peptide
fragments indeed suggest that the chirality of the proline
residue does not change the conformational preference of
the preceding tyrosine (Table 3). However, the residues
following proline are directed to different spatial regions,
because of inversion of the (Pro) dihedral angle. Stereo-
chemical inversion at Pro results in an opposite spatial
arrangement of Trp in the two peptides (Fig. 7), as the NMR
data showed NOE cross-peaks between Trp and Pro side
chains in the inactive diastereoisomer, while these were
absent in EM1 (Table 2 and Podlogar et al., 1998). The
fourth position, Phe4, while less structurally defined, occu-
pies distinct spatial regions in the two peptides.
Molecular dynamics (MD) simulations in explicit solvent
provided additional insight into the structural properties of
the peptides. In agreement with the NMR results, MD
trajectories showed stacking of Tyr, Pro, and Trp side
chains (structure A in Fig. 5 a) in [D-Pro2]EM1 but not in
EM1 (Podlogar et al., 1998). Simulations mirrored the rel-
ative rigidity of the Tyr-Pro-Trp region, as only two con-
formers were populated in both peptides (conformations A
and B in Fig. 5 a and Podlogar et al., 1998). The lack of
structural cross-peaks in the NOESY spectrum in water may
then be explained in terms of equilibrium between these two
conformations, while only one (A) is populated in DMSO.
The Phe residue, on the other hand, was free to sample the
conformational space, in agreement with the NMR data, in
which the NOE correlation of the Phe aromatic ring with
other side chains was not observed.
The ability of [D-Tyr1] and [D-Trp3] to fully activate the
-receptor, albeit with greatly reduced potency, may orig-
inate from partial similarity with the putative bioactive
conformation of EM1. MD trajectories of the backbone
atoms in the Pro-Trp-Phe of [D-Tyr1]EM1 are indeed similar
to those obtained for EM1 (Podlogar et al., 1998), indicating
that D-Tyr1 samples its conformational space independently
of the other residues. Using those conformations with

(Tyr)  65° and 	1(Tyr)  g
 (Fig. 5 b), it is possible to
overlap [D-Tyr1]EM1 with EM1, while the orientation of the
nitrogen group differs by 60o compared to EM1 (Fig. 7
and Table 4). The precise orientation of the Trp side chain
FIGURE 6 Distribution of dihedral angles during a 6.3-ns simulation of
solvated DAMGO. Angles shown:  (thin line), 
 (heavy line), 	1 (dashed
line).
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is left undetermined by the overlap, as only the t rotamer
was observed in MD trajectories of [D-Tyr1]EM1, while g	
and g
 conformations where observed as well for EM1
(Podlogar et al., 1998). The more severe reduction in po-
tency upon chirality inversion at Trp suggests that this
residue is more critical for receptor recognition.
A conformational search was conducted for [D-Trp3]EM1
by systematically varying the 
(Pro), (Trp), 
(Trp), and
	1(Trp) angles of [D-Trp
3]EM1 for a total of 648 starting
conformations. Of these, 49 unique structures were found
within 5 kcal/mol of the energy minimum. Conformations
with backbone dihedral angles similar to those of EM1 were
found within this set, but stereochemical inversion did not
allow precise geometrical overlap of the Trp side chains
(Fig. 7 and Table 4). The lower potency of the [D-Tyr1]EM1
and [D-Trp3]EM1 peptides may therefore be attributed to the
fact that conformations with arrangement of the backbone
dihedral angles similar to those of EM1 became energeti-
cally less favored (i.e., less populated) upon stereochemical
inversion. Alternatively, the peptides may assume a less
than ideal geometry of the three groups responsible for key
interaction with the -receptor, i.e., the charged ammonium
group and the Tyr and the Trp side chains. The effect of
stereochemical substitution becomes less detrimental farther
away from Pro (Table 1). The phenylalanine residue sam-
ples its conformational space independently of the other
residues, as shown by the NMR data and MD simulations of
EM1 (Podlogar et al., 1998), [D-Pro2]EM1 (Table 5), and
[D-Tyr1]EM1 (Fig. 5), and a similar behavior is therefore
expected for [D-Phe4]EM1. These results suggest that Phe4
is free to adopt a “bioactive” conformation at the receptor
site and that activation can occur independently of the
correct orientation and stereochemistry of this residue.
The solution structure of DAMGO has previously been
determined using NMR spectroscopy and conformational
analysis simulations (Penkler et al., 1993). A folded con-
TABLE 4 Torsion angles of the NMR and simulated structures of endomorphin-1 and diastereoisomers used in the
structural comparison*
Peptide
Tyr Pro Trp Phe

 	1  
  
 	1  
 	1
t-EM1† 133 
174 
61 166 
113 
32 
85 
124 120 
178
t-[D]-Pro2]EM1‡ 136 
174 68 139 
72 
34 
35 
127 157 45
t-D-Tyr1]EM1 65 
73 
74 146 
140 165 
167 
74 151 
167
t-[D-Trp3]EM1 136 
175 
59 163 
61 17 
78 
149 
56 
171
*Angles are in degrees.
†From Podlogar et al. (1998).
‡NMR-derived structure.
FIGURE 7 Comparison of EM1 (shown in red)
with [D-Pro2]EM1 (a), [D-Tyr1]EM1 (b), and
[D-Trp3]EM1 (c) (shown in blue). Representative
NMR-derived structures are chosen for the
[D-Pro2]EM1 and EM1 peptides. Conformation A
of Fig. 5 is used for [D-Tyr1]EM1.
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formation, characterized by a -II-like turn around Gly3-
MePhe4, was proposed for the trans isomer of this peptide,
but NMR experiments were not able to fully resolve the
structure of this peptide. Structural uncertainty in the “hinge
region” resulted in structures with a wide range of distances
and orientations between the two aromatic residues. Molec-
ular dynamics simulations of tTAGP obtained in this work
mirrored the flexibility of this peptide in solution. However,
comparison with the more rigid EM1 also revealed struc-
tural similarities between these two peptides. An overlap
between EM1 and representative DAMGO conformers
taken from the MD trajectory is shown in Fig. 8. The more
favored 	1(Tyr)  t rotamer (Penkler et al., 1993) was
chosen in the overlap. The comparison shows that Tyr1-
MePhe4 of DAMGO and Tyr1-Phe4 of EM1 can assume a
similar orientation with a separation between the aromatic
rings of 12 Å. The Trp residue of EM1 clearly appears as
an additional site, as overlap of this amino acid with
MePhe4 does not occur. Recent studies comparing EM1 and
DAMGO efficacy and potency at -opioid receptors have
yielded different results, depending on the type of experi-
ment performed and system used. EM1 has been reported to
act as a partial agonist, based on [35S]GTPS binding (Alt
et al., 1998; Harrison et al., 1998; Narita et al., 1998) and
autoradiography assay (Sim et al., 1998), but it has been
described as a full agonist in its ability to inhibit cAMP and
activate inwardly rectifying K	 channels (Gong et al.,
1998). The results shown here imply that the two peptides
may bind and activate the -receptor in a similar fashion.
However, the greater conformational flexibility of DAMGO
compared to EM1 does not exclude the existence of addi-
tional binding modes for DAMGO.
CONCLUSIONS
NMR and simulations data have shown that Pro2 provides
the necessary stereochemical requirements for activity of
EM1 at the -opioid receptor. Proline directs Trp3 toward a
-selectivity region in EM1, where the active conformation
is characterized by a structure in which the Tyr1 and Trp3
side chains have opposite orientations with respect to Pro2.
Such orientation is reversed in [D-Pro2]EM1, where side
chain–side chain interactions occur between Trp3 and Pro2.
This change in orientation results in the inability to activate
the receptor. The fourth residue of EM1 has a less stringent
stereochemical or conformational requirement, as loss in
potency is only 10-fold. Molecular dynamics simulations
and NMR data indeed show that this position is conforma-
tionally flexible and independent of the preceding three
FIGURE 8 Overlap of EM1 (shown in red)
with tTAGP (Tyr-D-Ala-Gly-MePhe-N-CH3)
(shown in blue). Representative tTAGP conform-
ers from the MD trajectory are aligned using a
rms fit of the first three residue backbone atoms.
EM1 is aligned with a rms fit of the nitrogen of
Tyr and the Tyr1 and Phe4 side chains.
TABLE 5 1H and 13C chemical shifts of [D-Pro2]EM1 in
DMSO-d6 at 25°C
Peak cis trans
YNH 8.11 (broad)
Y 4.24
Y 2.92/2.87
YOH 9.41 9.29
Y2,6 7.01 (123.42)
Y3,5 6.70 (114.32) 6.66
P 4.22 4.67, 4.30
P 1.62/1.35 (27.94) 1.88/1.45, 1.80/1.48
P 1.58/1.38 (23.02) 1.64
P 3.44 (49.73) 3.51
P 2.74 2.82
WNH 8.18 8.30
W 4.42 4.78, 4.51, 4.38
W 3.11/2.80 3.17/2.96, 2.92/2.77
W1 10.75 10.80
W2 7.05 (126.84) 7.07
W4 7.52 (119.86) 7.59
W5 6.47
W6 6.96 7.07
W7 7.30 7.29
W2 (135.04)
W2 (126.25)
FNH 7.95 7.79
F 4.49 4.47
F 3.03/2.84 3.04/2.88
F2,6 7.33
F3,5 7.39
13C chemical shifts are in parentheses. All values are ppm.
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amino acids. The result that [D-Tyr1]EM1, [D-Trp3]EM1,
and [D-Phe4]EM1 have full intrinsic activity with reduced
potency suggests that the region of the receptor responsible
for interaction with Tyr1 and Trp3 can tolerate different
orientations of these side chains and the tyramine chro-
mophore. Whether there is more than one bound conforma-
tion or a single conformation that is responsible for receptor
activation is not known. Comparison of EM1 and DAMGO
indicates that the two peptides can adopt similar conforma-
tions, characterized by a Tyr1-Phe4/MePhe4 distance of12
Å. However, EM1 has an additional recognition site at Trp,
while the greater flexibility of DAMGO may allow addi-
tional binding modes. The implication of dynamical prop-
erties of opioid peptides in the activation of the -opioid
receptors can be further explored by probing the binding of
accessible conformers to opioid receptor models.
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